跳至主要内容
临床试验/NCT02847052
NCT02847052已完成不适用

Study of the Role of Soluble Inhibitor of Interleukin 22, Interleukin 22 Binding Protein (IL-22BP), in Chronic Inflammatory Bowel Disease

Nantes University Hospital1 个研究点 分布在 1 个国家目标入组 52 人开始时间: 2014年8月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
52
试验地点
1
主要终点
Regulation of Interleukine 22 binding protein expression in Crohn's disease or Ulcerative colitis

研究概览

简要总结

IL-22 is an IL-10 family cytokine that plays major actions to increase intestinal epithelial barrier function and regeneration during experimental colitis. IL-22 binding protein is a small, soluble, and secreted protein potently inhibiting IL-22 actions through preventing the binding with IL-22 Recepteur. This study aims at characterizing how IL-22 binding protein is regulated in Inflammatory bowel disease to better understand the way IL-22 acts on epithelial cells during flares of the disease.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Crohn's disease or Ulcerative colitis
  • Healthy controls paired for age and sex
  • Samples availability in the biobank
  • Signed consent
  • No (Immune Mediated Inflammatory Disorders other than Inflammatory bowel disease
  • No other conditions predicted or known to affect IL-22/IL-22 recepteur /IL-22 binding protein regulation
  • Availability of clinical data
  • Age >18 y.o.
  • No pregnancy

排除标准

  • 未提供

结局指标

主要结局

Regulation of Interleukine 22 binding protein expression in Crohn's disease or Ulcerative colitis

时间窗: 1 day

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验